Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - Defendants are accused of overstating progress on prostate cancer therapeutic candidates [3]. - The quality and performance of the Company's supply chain and partners were allegedly exaggerated [3]. - As a result of these misrepresentations, statements regarding the Company's business and operations were claimed to be false or misleading [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on radiopharmaceutical development for cancer treatment [2].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 results showing a revenue decline in the Design IP segment to $425.9 million, a 7.7% decrease year-over-year, and a net income of $242.5 million, down 43% year-over-year [6]. Group 3: Market Reaction - Following the release of disappointing Q3 results, Synopsys stock fell nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60 (over 11%) from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to issues with customer experience, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48 (over 54%) from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The launch of Inspire V faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, captioned Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243 [3]. - Investors have until January 12, 2026, to request to be appointed to lead the case [3]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [4][5]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [4]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [6]. - Following an update on September 24, 2025, indicating two fatalities and a projected 4% and 6% decrease in copper and gold sales, the stock fell by $7.69 per share (almost 17%) [7]. - On September 25, 2025, reports of strained relations with the Indonesian government led to an additional drop of $2.33 per share (over 6%) [8]. - An Indonesian news report on September 28, 2025, suggested the incident was preventable, further impacting investor confidence [9].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly making false statements regarding product demand and inventory levels during the specified Class Period, leading to significant stock price decline after the truth was revealed [1][3]. Company Overview - James Hardie Industries plc is a multinational building materials company based in Dublin, Ireland, specializing in fiber cement and related construction products [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased James Hardie securities between May 20, 2025, and August 18, 2025, with a deadline for potential lead plaintiff representatives set for December 23, 2025 [2][4]. - The complaint alleges that despite internal data indicating reduced inventory levels as early as April 2025, the company misled investors by claiming strong demand and normal inventory levels [3]. Financial Impact - On August 19, 2025, James Hardie disclosed a 12% decline in segment sales and warned of ongoing weakness, resulting in a stock price drop of over 34% in a single trading day [3].

Core Points - Kaskela Law LLC has initiated an investigation into Priority Technology Holdings, Inc. (NASDAQ: PRTH) on behalf of long-term shareholders [1] - The investigation aims to determine if Priority and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2] Company Performance - Since February 2025, Priority's stock price has dropped from over $12.00 per share to below $6.00 per share, representing a decline of over 50% [2]

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].

Nov 24, 2025 9:20 AM Eastern Standard Time Freeport McMoRan Inc. (FCX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Robbins Geller Rudman & Dowd LLP Share SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the "Class Period†), have until January 12, 2026 to seek appointment ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Primo Brands Corporation regarding a class action lawsuit due to alleged false statements and supply disruptions following the merger with BlueTriton Brands [1][2]. Group 1: Allegations and Issues - The class action alleges that the defendants made false statements and concealed poor integration tracking of the merger between Primo Water and BlueTriton Brands, citing technology and service issues as contributing factors [2]. - Contrary to the defendants' claims of a "flawless" execution, significant supply disruptions were reported, which negatively impacted customers and the financial results of Primo Brands [2]. Group 2: Class Action Details - The class period for the lawsuit is from June 17, 2024, to November 6, 2025, and shareholders are encouraged to register for participation [2][3]. - The deadline for shareholders to seek lead plaintiff status is January 12, 2026, with no cost or obligation to participate in the case [3]. Group 3: Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].